NEUROPROTECTIVE PROPERTIES OF SELECTIVE PPAR GAMMA AGONIST LY554862

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目及 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 目的：探讨过氧化物酶体增殖物激活受体γ激动剂LY 554862对帕金森病的神经保护作用。 我们的实验室最近表明，长期口服吡格列酮诱导适度的 在灵长类动物模型中针对MPTP中毒的神经保护。根据这些信息，我们 继续研究PPAR-γ活化作为PD的可能治疗靶点。 这项研究使用了WNPRC Assay Services，是非人灵长类动物研究的先驱工作。 正在编写一份出版物。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Objective: To assess neuroprotective properties of the PPAR GAMMA AGONIST LY554862 in treating Parkinson's disease. Our laboratory has recently shown that chronic oral administration of pioglitazone induces modest neuroprotection against MPTP intoxication in a primate model. Based on this information we continued to investigate PPAR-¿ activation as a possible therapeutic target for PD. This research used WNPRC Assay Services and is precursor work to nonhuman primate studies. A publication is in preparation.